Fernando De la Garza-Salazar

Fernando De la Garza-Salazar

Auto-generated profile, based on publicly available information

Fernando De la Garza-Salazar

Tecnológico de Monterrey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2016 in Hematology
Verified
Journal Article
Closed access
AVAlberto Vazquez-Mellado
Alberto Vazquez-Mellado
MPMyrna Pequeño-Luévano
Myrna Pequeño-Luévano
OCOlga Graciela Cantu-Rodriguez
Olga Graciela Cantu-Rodriguez
LVLaura Villarreal-Martínez
Laura Villarreal-Martínez
JJJosé Carlos Jaime-Pérez
José Carlos Jaime-Pérez
DGDavid Gomez-Almaguer
David Gomez-Almaguer
Introduction: Thrombotic thrombocytopenic purpura (TTP) is characterized by a reduction in the von Willebrand cleavage protein ADAMTS-13, mainly as a consequence of autoimmunity. Plasma exchange (PEx) is standard, achieving complete remission (CR) in 77–83% of cases, but rates are variable depending on ADAMTS-13 activity and relapse is frequent in patients with <10%. Thus, an effective front-line immunosuppressive treatment is needed. Materials and methods: We administered PEx daily until CR and rituximab 100 mg/dose/week for 4 consecutive weeks to 10 patients with a first TTP episode and 1 relapsed patient (8 females (72%) and 3 males (28%)). Median age was 34 years (15–46) and laboratory parameters at diagnosis were as follows: platelets 11 × 109/l (range 7–27.4 × 109/l), lactate dehydrogenase 1822 U/l (range 705–8220 U/l, normal 70–180 U/l), and haemoglobin 6 g/dl (range 4.2–11.8 g/dl). ADAMTS-13 activity was determined in eight patients and was 15 units/ml in all (ref: negative 15 units/ml); Shiga toxin was negative in all patients. The median number of PEx until CR was 7 (range 4–12); prednisone 1 mg/kg was administered to six patients. Results: The median follow-up was 22 months (range 4–49) and the estimated 2-year relapse-free survival was 89%; one HIV+ patient relapsed at 8 months follow-up. No complications related to PEx or rituximab were reported. Conclusions: Our study suggests that low-dose rituximab and PEx are effective as front-line treatment for acute TTP; however, a prospective trial is needed to demonstrate whether low-dose rituximab is as effective as the conventional dose.

22 November 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
FGFernando De la Garza‐Salazar
Fernando De la Garza‐Salazar
PCPerla Rocío Colunga‐Pedraza
Perla Rocío Colunga‐Pedraza
DGDavid Gómez‐Almaguer
David Gómez‐Almaguer

13 May 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FGFernando De La Garza-Salazar
Fernando De La Garza-Salazar
MRMaria Elena Romero-Ibarguengoitia
Maria Elena Romero-Ibarguengoitia
ERElias Abraham Rodriguez-Diaz
Elias Abraham Rodriguez-Diaz
JAJose Ramón Azpiri-Lopez
Jose Ramón Azpiri-Lopez
AGArnulfo González-Cantú
Arnulfo González-Cantú
The electrocardiogram (ECG) is the most common tool used to predict left ventricular hypertrophy (LVH). However, it is limited by its low accuracy (<60%) and sensitivity (30%). We set forth the hypothesis that the Machine Learning (ML) C5.0 algorithm could optimize the ECG in the prediction of LVH by echocardiography (Echo) while also establishing ECG-LVH phenotypes. We used Echo as the standard diagnostic tool to detect LVH and measured the ECG abnormalities found in Echo-LVH. We included 432 patients (power = 99%). Of these, 202 patients (46.7%) had Echo-LVH and 240 (55.6%) were males. We included a wide range of ventricular masses and Echo-LVH severities which were classified as mild (n = 77, 38.1%), moderate (n = 50, 24.7%) and severe (n = 75, 37.1%). Data was divided into a training/testing set (80%/20%) and we applied logistic regression analysis on the ECG measurements. The logistic regression model with the best ability to identify Echo-LVH was introduced into the C5.0 ML algorithm. We created multiple decision trees and selected the tree with the highest performance. The resultant five-level binary decision tree used only six predictive variables and had an accuracy of 71.4% (95%CI, 65.5–80.2), a sensitivity of 79.6%, specificity of 53%, positive predictive value of 66.6% and a negative predictive value of 69.3%. Internal validation reached a mean accuracy of 71.4% (64.4–78.5). Our results were reproduced in a second validation group and a similar diagnostic accuracy was obtained, 73.3% (95%CI, 65.5–80.2), sensitivity (81.6%), specificity (69.3%), positive predictive value (56.3%) and negative predictive value (88.6%). We calculated the Romhilt-Estes multilevel score and compared it to our model. The accuracy of the Romhilt-Estes system had an accuracy of 61.3% (CI95%, 56.5–65.9), a sensitivity of 23.2% and a specificity of 94.8% with similar results in the external validation group. In conclusion, the C5.0 ML algorithm surpassed the accuracy of current ECG criteria in the detection of Echo-LVH. Our new criteria hinge on ECG abnormalities that identify high-risk patients and provide some insight on electrogenesis in Echo-LVH.

26 April 2022 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
PCPerla R. Colunga-Pedraza
Perla R. Colunga-Pedraza
SPSamantha P. Peña-Lozano
Samantha P. Peña-Lozano
ESErnesto Sánchez-Rendón
Ernesto Sánchez-Rendón
FGFernando De la Garza-Salazar
Fernando De la Garza-Salazar
JCJulia E. Colunga-Pedraza
Julia E. Colunga-Pedraza
DGDavid Gómez-Almaguer
David Gómez-Almaguer

13 December 2023 in Journal of Electrocardiology
Verified
Journal Article
Closed access
FSFernando De la Garza Salazar
Fernando De la Garza Salazar
BEBrian Egenriether
Brian Egenriether

30 November 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FSFernando De la Garza Salazar
Fernando De la Garza Salazar
MRMaria Elena Romero-Ibarguengoitia
Maria Elena Romero-Ibarguengoitia
JLJosé Ramón Azpiri López
José Ramón Azpiri López
AGArnulfo González-Cantú
Arnulfo González-Cantú
Background: Left ventricular hypertrophy detected by echocardiography (Echo-LVH) is an independent predictor of mortality. Integration of the Philips DXL-16 algorithm into the electrocardiogram (ECG) extensively analyses the electricity of the heart. Machine learning techniques such as the C5.0 could lead to a new decision tree criterion to detect Echo-LVH. Objectives: To search for a new combination of ECG parameters predictive of Echo-LVH. The final model is called the Cardiac Hypertrophy Computer-based model (CHCM). Methods: We extracted the 458 ECG parameters provided by the Philips DXL-16 algorithm in patients with Echo-LVH and controls. We used the C5.0 ML algorithm to train, test, and validate the CHCM. We compared its diagnostic performance to validate state-of-the-art criteria in our patient cohort. Results: We included 439 patients and considered an alpha value of 0.05 and a power of 99%. The CHCM includes T voltage in I (≤0.055 mV), peak-to-peak QRS distance in aVL (>1.235 mV), and peak-to-peak QRS distance in aVF (>0.178 mV). The CHCM had an accuracy of 70.5% (CI95%, 65.2–75.5), a sensitivity of 74.3%, and a specificity of 68.7%. In the external validation cohort (n = 156), the CHCM had an accuracy of 63.5% (CI95%, 55.4–71), a sensitivity of 42%, and a specificity of 82.9%. The accuracies of the most relevant state-of-the-art criteria were: Romhilt-Estes (57.4%, CI95% 49–65.5), VDP Cornell (55.7%, CI95%47.6–63.7), Cornell (59%, CI95%50.8–66.8), Dalfó (62.9%, CI95%54.7–70.6), Sokolow Lyon (53.9%, CI95%45.7–61.9), and Philips DXL-16 algorithm (54.5%, CI95%46.3–62.5). Conclusion: ECG computer-based data and the C5.0 determined a new set of ECG parameters to predict Echo-LVH. The CHCM classifies patients as Echo-LVH with repolarization abnormalities or LVH with increased voltage. The CHCM has a similar accuracy, and is slightly more sensitive than the state-of-the-art criteria.